Jasper Therapeutics

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REDWOOD CITY, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data on JSP191 showing long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting.

Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting

Jasper Therapeutics is advancing safer and more effective conditioning agents for stem cell transplantation and engineered hematopoietic stem cell therapies. The Company's lead compound, JSP191, originally discovered by Amgen, is a targeted, humanized monoclonal antibody.

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

The stock price of Jasper Therapeutics Inc (NASDAQ: JSPR) increased by over 8% pre-market today. This is why it happened.

Jasper Therapeutics (JSPR) Stock: Why The Price Increased Today

REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced results for the quarter ended September 30, 2021, and provided a business update.

Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman, and Chief Executive Officer, will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on Wednesday, November 10, 2021, at 11:40 a.m. Pacific Time.

Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference

NRX Pharmaceuticals

These two tiny drugmakers could make early shareholders wealthy.

2 Biotech Stocks Poised for Jaw-Dropping Growth

Jasper Therapeutics Inc (NASDAQ: JSPR) is trading lower Thursday amid profit taking after the stock rallied roughly 120% on Wednesday. Jasper Therapeutics surged higher Wednesday after Oppenheimer analyst Jay Olson initiated coverage on the stock with an Outperform rating and announced a price target of $21.

Why Jasper Therapeutics Stock Is Falling Today

Jasper Therapeutics (JSPR) stock is taking off on Wednesday thanks to a new bullish call from Oppenheimer analyst Jay Olson. The post JSPR Stock: The Bullish Call That Has Biotech Play Jasper Therapeutics Rocketing 105% Today appeared first on InvestorPlace.

JSPR Stock: The Bullish Call That Has Biotech Play Jasper Therapeutics Rocketing 105% Today

A Wall Street investment bank just started following the company with a very upbeat outlook.

Why Jasper Therapeutics Stock Is Jumping Today

The stock price of Jasper Therapeutics Inc (NASDAQ: JSPR) increased by over 139% during intraday trading today. This is why it happened.

JSPR Stock: Why It Drastically Increased Today

Jasper Therapeutics Inc (NASDAQ: JSPR) is surging higher Wednesday after Oppenheimer analyst Jay Olson initiated coverage on the stock with an Outperform rating and announced a price target of $21. The Oppenheimer analyst cited the potential of Jasper Therapeutics' conditioning agents for hematopoietic stem cell transplantation.

Why Jasper Therapeutics Stock Is Soaring Today

Shares of Jasper Therapeutics Inc. JSPR, +111.15% soared 106.2% in volatile morning trading, enough to pace the Nasdaq's gainers, after Oppenheimer analyst Jay Olson's bullish endorsement the day after the stock closed at a record low. The stock had been halted for volatility twice in the first half hour after the open, as trading volume swelled to 20.7 million shares.

Jasper Therapeutics' stock more than doubles after Oppenheimer analyst's bullish call

The stock price of Jasper Therapeutics (NASDAQ: JSPR) increased by over 15% pre-market. This is why it happened.

JSPR Stock: Why It Increased Today

News for Jasper Therapeutics Stock (JSPR)